Article Information
History
- December 12, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Mengyao Wu1,
- Tak-Ho Lo1,
- Liping Li2,
- Jia Sun2,
- Chujun Deng1,
- Ka-Ying Chan1,
- Xiang Li1,
- Steve Ting-Yuan Yeh3,
- Jimmy Tsz Hang Lee4,5,
- Pauline Po Yee Lui6,
- Aimin Xu4,5 and
- Chi-Ming Wong1,5,7,*
- 1Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China
- 2Zhujiang Hospital, Southern Medical University, China
- 3Ionis Pharmaceuticals, USA
- 4Department of Medicine, The University of Hong Kong, Hong Kong SAR, China
- 5The State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong SAR, China
- 6Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong SAR, China
- 7Hong Kong Polytechnic University Shenzhen Research Institute, China
- ↵*Correspondence: chi-ming.cm.wong{at}polyu.edu.hk; Tel.: 852-34008564
Posted December 12, 2022.
Amelioration of non-alcoholic fatty liver disease by targeting G protein-coupled receptor 110: A preclinical study
